Picardi M, Vincenzi A. Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”. Haematologica 2026; 111(9):3178-3180; https://doi.org/10.3324/haematol.2026.301044.